Advertising
Showing 1 to 15 of 23 entries
BUY
Licenses existing drugs with a smaller customer base from companies outside NA. Interesting new product that combines Advil and Tylenol in one dose. Market's underestimating how this will impact top and bottom lines. High and consistent ROIC, buying back shares, undervalued, free cashflow yield is 6%, founder run.
Consumer Products
TOP PICK
An in-licensing/marketing company to get pharmaceutical products to doctors and consumers. It had a huge run-up five years ago, but has since gone sideways. A growth company, so earnings and revenues have been increasing nicely. The CEO owns 17% of stock. They have no debt, are net cash. They launched some new products that the market needs to pick up on. Well-run. The valuation is now attractive. Now is the time to start a position. (Analysts’ price target is $8.00)
Consumer Products
PAST TOP PICK

(A Top Pick March 29/17, Up 33%) They license health care products from outside of Canada. They have been very good at providing consistent return on equity as well as earnings growth. This year will be an interesting time. They are sitting on almost $20 Million as a war chest and adding to it every quarter. They are searching for opportunities and will be diligent in deploying it. They are an under the radar company.

Consumer Products
PAST TOP PICK

(A Top Pick July 4/16. Up 4.26%.) They in-license products from companies that don’t have a marketing presence of pharmaceutical products in Canada. A very, very well-run company. A nice ROE at just under 30%. Have 2 new cardiology products that should be coming online towards the end of 2018-2019. No debt and about $14 million in cash.

Consumer Products
TOP PICK

A pharma company, but not one that does research and trials. They license products. Their CEO is excellent and they are a very well run company. Growth will come from their existing product suite plus additionally 3 more products. They are active on the business development front. (Analysts’ target: $9.13).

Consumer Products
PAST TOP PICK

(A Top Pick July 4/16. Down 10.97%.) This in-licenses products and solutions from companies that are generally situated in Europe. They generally bring in in-licenses for companies that don’t want to set up their own sales force. A very consistent ROE generator. EPS has flatlined here, but he is optimistic that they are going to be getting back to a growth phase.

Consumer Products
HOLD

A bit tricky, because there is not necessarily a catalyst for earnings to really move in the near future. $9-$10 would be his more immediate target price. Extremely well-run. Very consistent ROE generator, and have been growing their earnings fabulously over the last 5 years or so. Have some new products they are going to be launching towards the end of 2017, which will be the impetus to see earnings and subsequently the stock to move higher. He likes this for the long-term.

Consumer Products
PAST TOP PICK

(A Top Pick July 4/16. Up 0.61%.) He still likes this. Recently came out with Q2 results which were quite good. Top line growth was about 17%. Very consistent ROE generators. Just announced 2 cardiology products they are going to be launching in Q3, which at peak revenue generation should increase revenues by 60%. Excellent management.

Consumer Products
TOP PICK

A small growth company, very consistent ROE generator. They recently announced licensing of two cardiology products that should increase revenue by 60% and they recently broke out of a trading range.

Consumer Products
BUY

Had been built around a single product that related to iron deficiency. They have taken fairly high levels of profitability and have been picking up other stuff, and a lot of those other drugs have taken time to get a sales channel. Now that we are into 2016, those other products are starting to contribute, so the dependency on a single drug is getting smaller and smaller. Stock had a huge run up, and got really overvalued. They put out a great set of results on Friday. ROE is still above 30%, and is trading at about 18X 2016 earnings. The stock had a correction and then stabilized at the $6.50-$7 level, and he thinks the stock is going to start to advance. Emerging as a nice, high quality stock.

Consumer Products
PAST TOP PICK

(A Top Pick Dec 24/14. Down 31.61%.) Great company. Share price has not performed very well. They have delivered great results since then, but we have seen all this multiple contraction in the healthcare sector. Fairly narrowly focused around 1 drug. Its value is starting to get to the point where people are going to start to nibble. Be patient.

Consumer Products
PAST TOP PICK

(A Top Pick Dec 24/14. Down 31.71%.) This stock came down early in the year because of concerns about their over focus on a single product. Corrected earlier in the year and has just been trading sideways. Looks cheap. He expects it will bounce back with the rest of the sector.

Consumer Products
BUY

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

Consumer Products
PAST TOP PICK

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

Consumer Products
BUY

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

Consumer Products
Showing 1 to 15 of 23 entries

BioSyent Inc(RX-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for BioSyent Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

BioSyent Inc(RX-X) Frequently Asked Questions

What is BioSyent Inc stock symbol?

BioSyent Inc is a Canadian stock, trading under the symbol RX-X on the TSX Venture Exchange (RX-CV). It is usually referred to as TSXV:RX or RX-X

Is BioSyent Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about RX-X. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for BioSyent Inc.

Is BioSyent Inc a good investment or a top pick?

BioSyent Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for BioSyent Inc.

Why is BioSyent Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is BioSyent Inc worth watching?

1 stock analyst on Stockchase covered BioSyent Inc In the last year. It is a trending stock that is worth watching.

What is BioSyent Inc stock price?

On 2021-10-21, BioSyent Inc (RX-X) stock closed at a price of $6.91.